Table 5_A Bayesian network meta-analysis: evaluating the efficacy and safety of targeted t

A 2026 Bayesian network meta-analysis of 9 randomized controlled trials involving 1,760 patients with metastatic or advanced radioiodine-refractory differentiated thyroid cancer. The dataset, authored by Pin Wang and shared on figshare, compares the efficacy and safety of targeted therapies like lenvatinib, anlotinib, apatinib, and cabozantinib against placebo. It includes results for progression-free survival, overall survival, objective response rate, and adverse events.

Use Cases

• Compare the progression-free survival benefit of different tyrosine kinase inhibitors based on reported hazard ratios.
• Rank treatment safety profiles based on the reported surface under the cumulative ranking curve (SUCRA) values for adverse events.
• Analyze time-dependent efficacy patterns of therapies like apatinib based on the described waning benefit after 6-9 months.
• Evaluate the objective response rate of lenvatinib versus other treatments based on the reported odds ratio.

Strengths

• Analysis is based on 9 randomized controlled trials, a standard for clinical evidence.
• Includes data from 1,760 patients, providing a substantial sample for the meta-analysis.
• Uses Bayesian network meta-analysis methods, allowing for comparative ranking of multiple treatments.
• Reports specific statistical measures like hazard ratios, odds ratios, and SUCRA values for multiple endpoints.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• The dataset is very small at 49.5 KB, indicating it likely contains summary results rather than patient-level data.
• Data may reflect publication bias inherent to the systematic review and meta-analysis process.

Provenance

Source

figshare, author Pin Wang.

Collection Method

Systematic search of six electronic databases and subsequent Bayesian network meta-analysis of identified randomized controlled trials.

Freshness

Last updated 2026-03-18 07:35:11.